(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 104.25%.
IMMIX Biopharma's earnings in 2025 is -$23,562,837.On average, 4 Wall Street analysts forecast IMMX's earnings for 2025 to be -$27,057,050, with the lowest IMMX earnings forecast at -$26,325,052, and the highest IMMX earnings forecast at -$27,500,278.
In 2026, IMMX is forecast to generate -$25,002,084 in earnings, with the lowest earnings forecast at -$24,350,673 and the highest earnings forecast at -$25,384,872.